FDAnews
www.fdanews.com/articles/96677-quark-pharmaceuticals-inc-presented-positive-preclinical-results-of-systemic-rnai-compound-for-acute-renal-failure-arf

Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)

August 2, 2007

Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced the presentation of positive results from preclinical efficacy studies for its proprietary systemically-administered, siRNA compound, AKIi-5, in acute renal failure (ARF).
Earthtimes